|
|
|||||||||
Clinical Investigations |
1 Department of Nuclear Medicine, St. Vincents Catholic Medical Centers of New York, New York Medical College, Valhalla, New York
2 Department of Endocrinology, St. Vincents Catholic Medical Centers of New York, New York Medical College, Valhalla, New York
3 St. Vincents Comprehensive Cancer Center, St. Vincents Catholic Medical Centers of New York, New York Medical College, Valhalla, New York
4 Department of Surgery, St. Vincents Catholic Medical Centers of New York, New York Medical College, Valhalla, New York
Multicentric or multifocal breast cancer is considered as one of the limitations for sentinel lymph node (SLN) localization. We did a retrospective analysis to evaluate the success rate, sensitivity, accuracy, and negative predictive values of SLN localization in multicentric or multifocal breast lesions. Methods: Fifty-nine patients with multifocal or multicentric breast lesions proven by either fine-needle aspiration (19/59), core biopsy (39/59), or lumpectomy (8/59) underwent SLN localization. Of these patients, 46 had SLN localization by both radiocolloid and blue dye, and 13 had SLN localization by radiocolloid alone. Approximately 10 MBq 99mTc-labeled unfiltered sulfur colloid in 0.30.4 mL were injected intradermally over the 1 or 2 breast tumor locations 24 h before surgery. During surgery, vital blue dye was injected intraparenchymally in 46 places around the tumor. All lymph nodes with counts of >10 times that of the background counts, whether or not blue dye positive, and all blue dye-positive lymph nodes, whether or not radiocolloid positive, were excised and labeled accordingly. All lymph nodes underwent frozen sectioning and were examined by hematoxylin and eosin and immunohistologic (cytokeratin) staining. Results: Of the 59 patients, 48 had axillary lymph node dissection irrespective of the results of pathologic examination of the SLN. The success rate, sensitivity, negative predictive value, and accuracy were 93%, 100%, 100%, and 100% using the radiocolloid probe, 87%, 100%, 100%, and 100% using blue dye, and 93.5%, 100%, 100%, and 100% using combined methods, respectively. Concordance between blue dye and radiocolloid was 91% (the incidence of the number of sentinel nodes detected was 37.5%, 30.3%, 10.7%, and 21.4% for 1, 2, 3, and 4 or more lymph nodes, respectively). Metastatic lymph node involvement was found in 39.5% of patients. Conclusion: The sentinel node localization approach showed a high negative predictive value in breast cancer patients with multifocal or multicentric lesions, contrary to the common belief of significant false-negative results in these patients.
Key Words: multifocal or multicentric breast cancer sentinel lymph node 99mTc-sulfur colloid
-probe isosulfan blue vital dye
This article has been cited by other articles:
![]() |
S. Giard, M.-P. Chauvet, N. Penel, H. Mignotte, P. Martel, C. Tunon de Lara, P. Gimbergues, P. Dessogne, J.-M. Classe, E. Fondrinier, et al. Feasibility of sentinel lymph node biopsy in multiple unilateral synchronous breast cancer: results of a French prospective multi-institutional study (IGASSU 0502) Ann. Onc., January 20, 2010; (2010) mdp586v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Abe, R. A. Schmidt, K. Kulkarni, C. A. Sennett, J. S. Mueller, and G. M. Newstead Axillary Lymph Nodes Suspicious for Breast Cancer Metastasis: Sampling with US-guided 14-Gauge Core-Needle Biopsy--Clinical Experience in 100 Patients1 Radiology, January 1, 2009; 250(1): 41 - 49. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Abe, R. A. Schmidt, K. Kulkarni, C. A. Sennett, J. S. Mueller, and G. M. Newstead Axillary Lymph Nodes Suspicious for Breast Cancer Metastasis: Sampling with US-guided 14-Gauge Core-Needle Biopsy--Clinical Experience in 100 Patients Radiology, October 27, 2008; (2008) 2493071483. [Abstract] [Full Text] |
||||
![]() |
H. Abe, R. A. Schmidt, C. A. Sennett, A. Shimauchi, and G. M. Newstead US-guided Core Needle Biopsy of Axillary Lymph Nodes in Patients with Breast Cancer: Why and How to Do It RadioGraphics, October 1, 2007; 27(suppl_1): S91 - S99. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. H. Lyman, A. E. Giuliano, M. R. Somerfield, A. B. Benson III, D. C. Bodurka, H. J. Burstein, A. J. Cochran, H. S. Cody III, S. B. Edge, S. Galper, et al. American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer J. Clin. Oncol., October 20, 2005; 23(30): 7703 - 7720. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. M. Kuerer and L. A. Newman Lymphatic Mapping and Sentinel Lymph Node Biopsy for Breast Cancer: Developments and Resolving Controversies J. Clin. Oncol., March 10, 2005; 23(8): 1698 - 1705. [Full Text] [PDF] |
||||
![]() |
A. Chagpar, R. C. Martin III, C. Chao, S. L. Wong, M. J. Edwards, T. Tuttle, and K. M. McMasters Validation of Subareolar and Periareolar Injection Techniques for Breast Sentinel Lymph Node Biopsy Arch Surg, June 1, 2004; 139(6): 614 - 620. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |